Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells

Experimental Cell Research

Volumn 285, Issue 1, 2003, Pages 39-49

  Nagy, Peter ^a   Arndt Jovin, Donna J ^a   Jovin, Thomas M ^a  

^a MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

EGF receptor; ErbB1; Inhibition of proliferation; RNA interference

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; MESSENGER RNA;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

MAMMALIA;

EID: 0037446068     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00050-2     Document Type: Article

References (50)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:2001;127-137.
2. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities . Eur. J. Cancer. 37:(Suppl. 4):2001;S3-S8.
3. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16:1996;5276-5287.
4. Moasser M.M., Basso A., Averbuch S.D., Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188.
5. Shawver L.K., Slamon D., Ullrich A. Tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1:2002;117-123.
6. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
7. Baselga J. Phase I and II clinical trials of trastuzumab. Ann. Oncol. 12:(Suppl. 1):2001;S49-S55.
8. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., Slamon D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:1998;2659-2671.
9. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232.
10. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
11. Shin D.M., Donato N.J., Perez-Soler R., Shin H.J., Wu J.Y., Zhang P., Lawhorn K., Khuri F.R., Glisson B.S., Myers J., Clayman G., Pfister D., Falcey J., Waksal H., Mendelsohn J., Hong W.K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7:2001;1204-1213.
12. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063.
13. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer. 37:(Suppl. 4):2001;S16-S22.
14. Bishop P.C., Myers T., Robey R., Fry D.W., Liu E.T., Blagosklonny M.V., Bates S.E. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene. 21:2002;119-127.
15. Fang K., Chen M.H. Transfection of anti-sense complementary DNA of human epidermal-growth-factor receptor attenuates the proliferation of human non-small-cell-lung-cancer cells. Int. J. Cancer. 81:1999;471-478.
16. Jen K.Y., Gewirtz A.M. Suppression of gene expression by targeted disruption of messenger RNA available options and current strategies . Stem Cells. 18:2000;307-319.
17. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
18. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
19. Miyagishi M., Taira K. U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. 20:2002;497-500.
20. Filmus J., Pollak M.N., Cailleau R., Buick R.N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 128:1985;898-905.
21. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
22. H.M. Shapiro, Overture, in: Practical Flow Cytometry, Wiley-Liss, New York, 1995.
23. Kehlenbach R.H., Dickmanns A., Gerace L. Nucleocytoplasmic shuttling factors including Ran and CRM1 mediate nuclear export of NFAT in vitro. J. Cell Biol. 141:1998;863-874.
24. Brock R., Hamelers I.H., Jovin T.M. Comparison of fixation protocols for adherent cultured cells applied to a GFP fusion protein of the epidermal growth factor receptor. Cytometry. 35:1999;353-362.
25. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225.
26. Arteaga C.L., Johnson D.H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol. 13:2001;491-498.
27. Campbell D.H., Sutherland R.L., Daly R.J. Signaling pathways and structural domains required for phosphorylation of EMSI/cortactin. Cancer Res. 59:1999;5376-5385.
28. Cao L., Yao Y., Lee V., Kiani C., Spaner D., Lin Z., Zhang Y., Adams M.E., Yang B.B. Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. J. Cell Biochem. 77:2000;569-583.
29. Ringerike T., Stang E., Johannessen L.E., Sandnes D., Levy F.O., Madshus I.H. High-affinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A). J. Biol. Chem. 273:1998;16639-16642.
30. Baulida J., Kraus M.H., Alimandi M., Di Fiore P.P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:1996;5251-5257.
31. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:1999;60-70.
32. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases implications for cancer therapy . EMBO J. 21:2002;2407-2417.
33. Merlino G.T., Xu Y.H., Ishii S., Clark A.J., Semba K., Toyoshima K., Yamamoto T., Pastan I. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science. 224:1984;417-419.
34. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:1998;806-811.
35. Nagy P., Jenei A., Kirsch A.K., Szöllösi J., Damjanovich S., Jovin T.M. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J. Cell. Sci. 112:1999;1733-1741.
36. Brock R., Jovin T.M. Heterogeneity of signal transduction at the subcellular level microsphere-based focal EGF receptor activation and stimulation of Shc translocation . J. Cell Sci. 114:2001;2437-2447.
37. Verveer P.J., Wouters F.S., Reynolds A.R., Bastiaens P.I. Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane. Science. 290:2000;1567-1570.
38. Haj F.G., Verveer P.J., Squire A., Neel B.G., Bastiaens P.I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science. 295:2002;1708-1711.
39. Huang C.Y., Ferrell J.E. Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 93:1996;10078-10083.
40. Busse D., Doughty R.S., Ramsey T.T., Russell W.E., Price J.O., Flanagan W.M., Shawver L.K., Arteaga C.L. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires upregulation of p27KIP1 independent of MAPK activity. J. Biol. Chem. 275:2000;6987-6995.
41. Liu B., Fang M., Schmidt M., Lu Y., Mende Isohn J., Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer. 82:2000;1991-1999.
42. Modjtahedi H., Affleck K., Stubberfield C., Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol. 13:1998;335-342.
43. Kim E.S., Khuri F.R., Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. 13:2001;506-513.
44. Albanell J., Codony-Servat J., Rojo F., Del Campo J.M., Sauleda S., Anido J., Raspall G., Giralt J., Rosello J., Nicholson R.I., Mendelsohn J., Baselga J. Activated extracellular signal-regulated kinases association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments . Cancer Res. 61:2001;6500-6510.
45. Adamson E.D. EGF receptor activities in mammalian development. Mol. Reprod. Dev. 27:1990;16-22.
46. Baselga J., Pfister D., Cooper M.R., Cohen R., Burtness B., Bos M., D'Andrea G., Seidman A., Norton L., Gunnett K., Falcey J., Anderson V., Waksal H., Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18:2000;904-914.
47. Herbst R.S., Maddox A.M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., Rojo F., Hong W.K., Swaisland H., Averbuch S.D., Ochs J., LoRusso P.M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors results of a phase I trial . J. Clin. Oncol. 20:2002;3815-3825.
48. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.
49. Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science. 296:2002;1270-1273.
50. Sijen T., Fleenor J., Simmer F., Thijssen K.L., Parrish S., Timmons L., Plasterk R.H., Fire A. On the role of RNA amplification in dsRNA-triggered gene silencing. Cell. 107:2001;465-476.